Genetic Disorders Partnering Terms and Agreements

The Genetic Disorders Partnering Terms and Agreements report provides a detailed understanding and analysis of how and why companies enter genetic disorders partnering deals. The majority of deals are discovery, preclinical or development stage whereby the licensee obtains a right or an option right to license the licensors technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest genetic disorders deals and contracts announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
The report includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. The initial chapters of this report provide an orientation of genetic disorders dealmaking and business activities. Chapter 1 provides an introduction to the report.
Chapter 2 provides an overview of the trends in genetic disorders dealmaking since 2007 covering trends by year, deal type, stage of development, technology type and therapeutic indication. In addition the chapter includes an analysis of financial deal terms by stage at signing covering headline value, upfront payment, milestone payments and royalty rates. Analysis includes median values and distribution of values for each stage of development.
Chapter 3 provides a review of the leading genetic disorders deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary followed by a comprehensive listing of genetic disorder deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides comprehensive access to all deals since 2007 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive directory of all genetic disorder partnering deals signed and announced since 2007. The chapter is organized by specific genetic disorder therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided with each report of all genetic disorders partnering deals signed and announced since 2007. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in genetic disorders partnering and dealmaking since 2007.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of genetic disorders technologies and products.
Benefits
Key benefits
Genetic Disorders Partnering Terms and Agreementsprovides the reader with the following key benefits:
• In-depth understanding of genetic disorders deal trends since 2007
• Access genetic disorders deal headline, upfront, milestone and royalty data
• Research hundreds of actual contracts between genetic disorders partner companies
• Comprehensive access to links to actual genetic disorders deals entered into by the world’s biopharma companies
• Indepth review of genetic disorders deals entered into by the leading fifty bigpharma companies
• Benchmark the key deal terms companies have agreed in previous deals
• Identify key terms under which companies partner genetic disorders opportunities
• Uncover companies actively partnering genetic disorders opportunities
Report scope
Genetic Disorders Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to genetic disorders trends and structure of deals entered into by leading companies worldwide.
Genetic Disorders Partnering Terms and Agreements includes:
o Trends in genetic disorders dealmaking in the biopharma industry since 2007
o Analysis of genetic disorders deal structure
o Access to headline, upfront, milestone and royalty data
o Access to genetic disorders deal contract documents
o Comprehensive access to genetic disorders deal records
o The leading genetic disorders deals by value since 2007
o Most active genetic disorders dealmakers since 2007
In Genetic Disorders Partnering Terms and Agreements, available deals and contracts are listed by:
o Headline value
o Upfront payment value
o Royalty rate value
o Stage of development at signing
o Deal component type
o Technology type
o Specific therapy indication
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
This on-demand report will be delivered by publisher within 1-3 days after receipt of order

Table of contents



Executive Summary

Chapter 1 – Introduction



Chapter 2 – Trends in genetic disorders dealmaking

2.1. Introduction

2.2. Genetic disorders partnering over the years

2.3. Bigpharma genetic disorders dealmaking activity

2.4. Bigpharma not active in genetic disorders

2.5. Genetic disorders partnering by deal type

2.6. Genetic disorders partnering by industry sector

2.7. Genetic disorders partnering by stage of development

2.8. Genetic disorders partnering by technology type

2.9. Genetic disorders partnering by dermatology indication

2.10. Average deal terms for genetic disorders

2.10.1 Genetic disorders headline values

2.10.2 Genetic disorders upfront payments

2.10.3 Genetic disorders milestone payments

2.10.4 Genetic disorders royalty rates



Chapter 3 – Leading genetic disorders deals

3.1. Introduction

3.2. Top genetic disorders deals by value

3.3. Top genetic disorders deals involving bigpharma



Chapter 4 – Bigpharma genetic disorders deals

4.1. Introduction

4.2. How to use bigpharma partnering deals

4.3. Bigpharma hospital care partnering company profiles

Abbott

Actavis

Actelion

Allergan

Amgen

Astellas

AstraZeneca

Baxter International

Bayer

Bristol-Myers

Squibb C

elgene

Eli Lilly

Endo Pharmaceuticals

Forest Laboratories

Galderma

GlaxoSmithKline

Hospira

Johnson & Johnson

Merck & Co

Merck KGaA

Mitsubishi Tanabe

Novartis

Pfizer

Roche

Sanofi

Shionogi

Shire

Teva

Warner Chilcott

Watson



Chapter 5 – Genetic disorders partnering contracts directory

5.1. Introduction

5.2. By deal type

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

Development

Distribution

Equity purchase

Joint venture

Licensing

Litigation

Loan

Manufacturing

Marketing

Option

Promotion

Research

Settlement

Sub-license

Supply

Termination

5.3. By stage of development

Discovery

Formulation

Marketed

Phase I

Phase II

Phase III

Preclinical

5.4. By technology type

Antibodies

Assays

Biologicalcompounds

Biomaterials

Clinical testing

Devices

Diagnostics

DNA probes

Drug delivery

Enabling technology

Equipment

Genomics

Natural product

Oligonucleotide

Orphan drug

Peptides

Processes

Recombinant DNA

Regenerative medicine

Research services

Research supplies

Screening

Small molecules

Stem cells



Chapter 6 – Genetic disorders dealmaking by indication

6.1. Introduction

6.2. Deals by therapeutic indication

Genetic disorders

Huntington''s disease

Down''s syndrome

Cystic fibrosis

Sickle cell

Neurofibromatosis

Fragile X syndrome

Hereditary angiodema

Other genetic disorders



Chapter 7 – Partnering resource center

7.1. Online partnering

7.2. Partnering events

7.3. Further reading on dealmaking



Appendices

Appendix 1 – Directory of genetic disorders deals by company A-Z 2007-2013

Appendix 2 – Directory of genetic disorders deals by deal type 2007-2013

Asset purchase

Assignment

Bigpharma outlicensing

Co-development

Collaborative R&D

Co-market

Contract service

Co-promotion

CRADA

Cross-licensing

Development

Distribution

Equity purchase

Evaluation

Grant

Joint venture

Licensing

Litigation

Loan

Manufacturing

Manufacturing - OEM

Marketing

Material transfer

Option

Promotion

Research

Royalty financing

Settlement

Spin out

Sub-license

Supply

Technology transfer

Termination

Warranty

Appendix 3 - Directory of Genetic disorders deals by stage of development 2007-2013

Appendix 4 – Directory of Genetic disorders deals by technology type 2007 - 2013

Appendix 5 – Deal type definitions



About Wildwood Ventures

Current Partnering

Current Agreements

Recent titles from CurrentPartnering

Order Form – Reports



Table of figures

Figure 1: Genetic disorders partnering since 2007

Figure 2: Bigpharma – top 50 – genetic disorders deals 2007 to 2013

Figure 3: Bigpharma genetic disorders deal frequency – 2007 to 2013

Figure 4: Inactive bigpharma in genetic disorders 2007-2013

Figure 5: Genetic disorders partnering by deal type since 2007

Figure 6: Genetic disorders partnering by industry sector since 2007

Figure 7: Genetic disorders partnering by stage of development since 2007

Figure 8: Genetic disorders partnering by technology type since 2007

Figure 9: Genetic disorders partnering by dermatology target since 2007

Figure 10: Genetic disorders deals with a headline value

Figure 11: Genetic disorders deal headline value distribution, US$million – discovery stage

Figure 12: Genetic disorders deal headline value distribution, US$million – preclinical stage

Figure 13: Genetic disorders deal headline value distribution, US$million – phase I stage

Figure 14: Genetic disorders deal headline value distribution, US$million – phase II stage

Figure 15: Genetic disorders deal headline value distribution, US$million – phase III stage

Figure 16: Genetic disorders deal headline value distribution, US$million – regulatory stage

Figure 17: Genetic disorders deal headline value distribution, US$million – marketed stage

Figure 18: Summary median headline value by stage of development, 2007-2013

Figure 19: Genetic disorders deals with upfront payment values

Figure 20: Genetic disorders deal upfront payment distribution, US$million – discovery stage

Figure 21: Genetic disorders deal upfront payment distribution, US$million – preclinical stage

Figure 22: Genetic disorders deal upfront payment distribution, US$million – phase I stage

Figure 23: Genetic disorders deal upfront payment distribution, US$million – phase II stage

Figure 24: Genetic disorders deal upfront payment distribution, US$million – phase III stage

Figure 25: Genetic disorders deal upfront payment distribution, US$million – regulatory stage

Figure 26: Genetic disorders deal upfront payment distribution, US$million – marketed stage

Figure 27: Summary median upfront payments by stage of development, 2007-2013

Figure 28: Genetic disorders deals with milestone payments

Figure 29: Genetic disorders deal milestone distribution, US$million – discovery stage

Figure 30: Genetic disorders deal milestone distribution, US$million – preclinical stage

Figure 31: Genetic disorders deal milestone distribution, US$million – phase I stage

Figure 32: Genetic disorders deal milestone distribution, US$million – phase II stage

Figure 33: Genetic disorders deal milestone distribution, US$million – phase III stage

Figure 34: Genetic disorders deal milestone distribution, US$million – regulatory stage

Figure 35: Genetic disorders deal milestone distribution, US$million – marketed stage

Figure 36: Genetic disorders deals with royalty rates, %

Figure 37: Genetic disorders deal royalty rate distribution, US$million – discovery stage

Figure 38: Genetic disorders deal royalty rate distribution, US$million – preclinical stage

Figure 39: Genetic disorders deal royalty rate distribution, US$million – phase I stage

Figure 40: Genetic disorders deal royalty rate distribution, US$million – phase II stage

Figure 41: Genetic disorders deal royalty rate distribution, US$million – phase III stage

Figure 42: Genetic disorders deal royalty rate distribution, US$million – regulatory stage

Figure 43: Summary median royalty rate by stage of development, 2007-2013

Figure 44: Top genetic disorders deals by value since 2007

Figure 45: Top genetic disorders deals signed by bigpharma value since 2007

Figure 46: Online partnering resources

Figure 47: Forthcoming partnering events